1. Exploitation of a novel biosensor based on the full-length human F508del-CFTR with computational studies, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue
- Author
-
Robert C. Ford, Andrea Ridolfi, Matteo Uggeri, Marco Rusnati, Pasqualina D'Ursi, Enrico Millo, Paola Fossa, Chiara Urbinati, Jack Clews, Xin Meng, Paolo Bergese, Nicoletta Pedemonte, Giulia Paiardi, Alessandro Orro, and Luciano Milanesi
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Computational chemistry ,02 engineering and technology ,Computational biology ,Molecular dynamics ,010402 general chemistry ,medicine.disease_cause ,01 natural sciences ,Cystic fibrosis ,chemistry.chemical_compound ,In vivo ,Biosensor ,CFTR ,Surface plasmon resonance ,Materials Chemistry ,medicine ,Bioassay ,Electrical and Electronic Engineering ,Instrumentation ,Mutation ,biology ,Chemistry ,Endoplasmic reticulum ,Lumacaftor ,technology, industry, and agriculture ,Metals and Alloys ,respiratory system ,021001 nanoscience & nanotechnology ,Condensed Matter Physics ,medicine.disease ,digestive system diseases ,Cystic fibrosis transmembrane conductance regulator ,respiratory tract diseases ,0104 chemical sciences ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials ,biology.protein ,0210 nano-technology - Abstract
Cystic fibrosis (CF) is mainly caused by the mutation F508del of the cystic fibrosis transmembrane conductance regulator (CFTR) that is thus retained in the endoplasmic reticulum and degraded. New drugs able to rescue F508del-CFTR trafficking and activity are eagerly awaited, a goal that requires the availability of computational and experimental models closely resembling the F508del-CFTR structure and environment in vivo. Here we describe the development of a biosensor based on F508del-CFTR in a lipid environment that proved to be endowed with a wider analytical potential in respect to the previous CFTR-based biosensors. Integrated with an appropriate computational model of the whole human F508del-CFTR in lipid environment and CFTR stability and functional assays, the new biosensor allowed the identification and characterization at the molecular level of the binding modes of some known F508del-CFTR-rescuing drugs and of a new aminoarylthiazole-Lumacaftor/Tezacaftor hybrid derivative endowed with promising F508del-CFTR-binding and rescuing activity.
- Published
- 2019